Bradley A. Keywell Sells 395,800 Shares of Tempus AI, Inc. (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) major shareholder Bradley A. Keywell sold 395,800 shares of Tempus AI stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $42.95, for a total transaction of $16,999,610.00. Following the transaction, the insider now owns 16,164,449 shares in the company, valued at approximately $694,263,084.55. This trade represents a 2.39 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Tempus AI Stock Down 2.4 %

NASDAQ:TEM opened at $41.00 on Friday. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55. The company has a 50 day moving average of $52.64. Tempus AI, Inc. has a 1 year low of $22.89 and a 1 year high of $79.49.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on TEM. Guggenheim assumed coverage on Tempus AI in a research report on Monday, December 9th. They issued a “buy” rating and a $74.00 price objective on the stock. Stifel Nicolaus cut shares of Tempus AI from a “buy” rating to a “hold” rating and raised their target price for the company from $45.00 to $65.00 in a research note on Monday, November 11th. Bank of America boosted their price target on shares of Tempus AI from $52.00 to $54.00 and gave the stock a “neutral” rating in a research note on Friday. Wolfe Research assumed coverage on Tempus AI in a report on Friday. They issued an “outperform” rating and a $60.00 target price on the stock. Finally, Piper Sandler reissued a “neutral” rating and set a $70.00 price target (up from $40.00) on shares of Tempus AI in a research note on Tuesday, November 12th. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Tempus AI currently has a consensus rating of “Moderate Buy” and a consensus target price of $56.00.

Institutional Trading of Tempus AI

Several hedge funds and other institutional investors have recently bought and sold shares of TEM. NEA Management Company LLC increased its position in Tempus AI by 17.8% during the third quarter. NEA Management Company LLC now owns 5,385,979 shares of the company’s stock valued at $304,846,000 after acquiring an additional 813,169 shares during the last quarter. Novo Holdings A S bought a new position in Tempus AI during the 2nd quarter valued at about $142,605,000. Revolution Growth Management Company Inc. purchased a new stake in Tempus AI in the 2nd quarter worth about $128,133,000. ARK Investment Management LLC lifted its stake in Tempus AI by 355.0% in the third quarter. ARK Investment Management LLC now owns 2,378,157 shares of the company’s stock worth $134,604,000 after purchasing an additional 1,855,459 shares during the last quarter. Finally, Alphabet Inc. purchased a new position in shares of Tempus AI during the second quarter valued at approximately $54,289,000. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.